Cidara Therapeutics Announces Upcoming Investor Conferences

Author: Logan Wright Updated: 09-04-2025 08:25 AM

Cidara Therapeutics Investor Conference Participation

Recently, Cidara Therapeutics, Inc. (NASDAQ: CDTX), a notable name in biotechnology, has shared its plans to engage in significant investor conferences this September. This participation highlights the company's commitment to innovative drug development through its proprietary Cloudbreak platform, which focuses on drug-Fc conjugate (DFC) therapeutics.

Details of the Conferences

Below are details regarding the upcoming conferences where Cidara will present:

H.C. Wainwright 27th Annual Global Investment Conference

Date: September 8, 2025
Time: 4:00 PM ET
Format: Corporate Presentation

Morgan Stanley 23rd Annual Global Healthcare Conference

Date: September 9, 2025
Time: 7:00 AM ET
Format: Fireside Chat

Cidara plans to hold one-on-one investor meetings during these events, offering a platform for deeper discussions about the company’s pioneering therapeutics.

Innovative Therapeutics at Cidara

Cidara Therapeutics is at the forefront of medical innovation, leveraging its Cloudbreak platform to create targeted drug-Fc conjugates. These therapeutics combine small molecules or peptides with a proprietary human antibody fragment to treat various health conditions effectively. Their leading DFC candidate, CD388, aims to provide long-lasting antiviral action against both seasonal and pandemic influenza with a single dose by blocking viral growth.

Additionally, in June 2023, the FDA provided Fast Track Designation for CD388, which signifies the drug's potential to meet unmet medical needs. This past June, Cidara announced promising top-line results from its Phase 2b NAVIGATE trial, reinforcing its commitment to advancing global health solutions.

Future Developments

The company has also diversified its research to include oncology, with the development of other DFCs. Notably, in July 2024, Cidara received clearance for its investigational new drug application for CBO421, specifically designed to target CD73 in various solid tumors. This wide-ranging approach not only showcases Cidara’s adaptability but also positions it as a key player in addressing critical health challenges.

Conclusion

Cidara Therapeutics continues to take significant strides in the biotech field, demonstrating innovative approaches to drug development and a proactive stance in investor relations. Their participation in major investor conferences this September will undoubtedly bolster their visibility and support for future projects.

Visit Us
For more detailed information about Cidara Therapeutics and its latest advancements, please visit www.cidara.com.

Investor Contact:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

Frequently Asked Questions

What is the Cloudbreak platform by Cidara Therapeutics?

The Cloudbreak platform is a proprietary technology used by Cidara to develop drug-Fc conjugate therapeutics aimed at various diseases.

What are DFC therapeutics?

DFC therapeutics are innovative treatments that combine small molecules or peptides with antibody fragments to enhance efficacy in disease treatment.

What is CD388?

CD388 is Cidara's leading antiviral candidate designed for universal prevention of influenza with a single long-acting dose.

What recent designations has CD388 received?

In June 2023, the FDA granted CD388 Fast Track Designation, highlighting its potential in treating significant health concerns.

How is Cidara expanding its research focus?

Cidara is also advancing into oncology, developing DFCs like CBO421 to target CD73 in solid tumors.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.